Royalty Pharma spent up to $950 million to acquire the royalties for Amgen's lung cancer drug

阿斯達克財經網
2025.08.25 16:31

生科公司 Royalty Pharma(RPRX.US) 週一公佈，已同意以高達 9.5 億美元的價格，向 BeOne Medicines 購買安進 (AMGN.US) 旗下小細胞肺癌藥物的特許經營權使用費權益。

該交易令 Royalty Pharma 將獲得 Imdelltra 療法全球淨銷售額的約 7%，該療法去年獲得美國批准，用於治療化療失敗的廣泛期小細胞肺癌患者。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.